CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-13 | Greenstreet Yvonne Chief Executive Officer | Grant or award | +3,859 | 82,739 | ||
| 2025-02-13 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +3,109 | 33,753 | ||
| 2025-02-13 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Grant or award 10b5-1 | +2,103 | 14,984 | ||
| 2025-02-13 | Garg Pushkal CMO & EVP Dev & Med Affairs | Grant or award 10b5-1 | +3,109 | 15,098 | ||
| 2025-01-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise 10b5-1 | +23,876 | $88.95 | $2.1M | 39,581 |
| 2025-01-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise 10b5-1 | +25,000 | $88.95 | $2.2M | 64,581 |
| 2025-01-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −52,592 | $285.00 | $15.0M | 11,989 |
| 2025-01-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise · Performance Stock Option 2015 (right to buy) 10b5-1 | −25,000 | 0 | ||
| 2025-01-27 | Garg Pushkal CMO & EVP Dev & Med Affairs | Option exercise · Stock Option (right to buy) 10b5-1 | −23,876 | 0 | ||
| 2025-01-23 | SHARP PHILLIP A Director | Option exercise 10b5-1 | +11,250 | $131.21 | $1.5M | 11,250 |
| 2025-01-23 | SHARP PHILLIP A Director | Sale 10b5-1 | −11,250 | $275.00 | $3.1M | 0 |
| 2025-01-23 | SHARP PHILLIP A Director | Option exercise · Stock Option (right to buy) 10b5-1 | −11,250 | 0 | ||
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −121 | $247.48 | $30K | 17,336 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −186 | $248.99 | $46K | 17,150 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −426 | $250.08 | $107K | 16,724 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −778 | $251.68 | $196K | 15,946 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −100 | $252.94 | $25K | 15,846 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −140 | $254.37 | $36K | 15,706 |
| 2024-12-12 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −1 | $255.80 | $256 | 15,705 |
| 2024-11-26 | Greenstreet Yvonne Chief Executive Officer | Sale | −93 | $247.77 | $23K | 84,006 |
Page 39 of 41 · 816 trades